The effect of Ascorbic Acid as supplementary treatment with risperidone in controlling the symptoms of schizophrenia: A double-blind, placebo-controlled clinical trial

Authors

  • Neda Alibeigi Department of Psychiatry, University of Welfare and Research Sciences, Tehran, Iran
  • Venous Mirzaei Department of Psychiatry, University of Welfare and Research Sciences, Tehran, Iran
Abstract:

Background and Objective: Considering the hypothesis of the effects of the use of antioxidants such as ascorbic acid on the improvement of oxidative stress induced by schizophrenia, the present study was designed to investigate the effect of ascorbic acid as an adjunctive therapy with risperidone in controlling the symptoms of schizophrenia. Materials and Methods: This randomized clinical trial was conducted on patients with schizophrenia admitted to Tehran's Razi hospital of psychiatry in 2018. The patients were divided into control and intervention groups. The group treated with ascorbic acid received this drug daily at 500 mg twice daily and the placebo group received a similar drug, similar to ascorbic acid, at the same rate for 4 months. The PANSS (Positive & Negative Symptom Scale) questionnaire was used to determine the status of the positive and negative symptoms and the SCORS (Schizophrenia Cognition Rating Scale) questionnaire was used to determine the cognitive status at the end of weeks 8 and 16 when entering the study. Data were analyzed using paired t-test and Wilcoxon in SPSS 20 software. Results: The effect of ascorbic acid on the positive and negative symptoms of patients at the 8th and 16th weeks showed that after eight weeks of treatment, among the positive symptoms, conceptual disorganization, excitement, hostility and grandiosity, among the negative symptoms, blunted affect has had a significant improvement relative to before intervention. After 16 weeks of treatment, except difficulty in abstract thinking, all of the symptoms showed a significant improvement compared with the symptoms of the patients before the study. Compared to ascorbic acid, the effect of placebo on all of the positive and negative symptoms and other symptoms in most cases was not significant. Regarding the effect of ascorbic acid on the cognitive symptoms of patients in the 8th and 16th week, there was no significant difference in the few numbers of cognitive symptoms in the eighth week, although after eight weeks, overall cognitive symptoms were significantly improved (p

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Treatment-Responsiveness of Negative Symptoms in Schizophrenia: A double-blind placebo-control clinical trial

Background: The negative symptoms of schizophrenia remain a major clinical challenge. Nortriptyline is a serotonin and noradrenalin reuptake inhibitor and belongs to secondary amine tricycles. The aim of this study is to evaluate the effect of nortriptyline on the negative symptoms of schizophrenia. Methods: This study is a six-week randomized placebo-control trial of nortriptyline or placebo a...

full text

Methoxsalen bath in the treatment of palmoplantar Eczema: A double-blind, placebo controlled clinical trial

Background: Palmoplantar eczema is a common clinical problem involving 2% of the population. There are many treatment modalities for palmoplantar eczema, each with specific local and systemic side effects. Objective: To evaluate methoxsalen bath in the treatment of palmoplantar eczema. Patients and Methods: In a randomized, double-blind, placebo controlled clinical trial, 60 patients with palmo...

full text

The Effect of Hydroxychloroquine on Symptoms of Knee Osteoarthritis: A Double-Blind Randomized Controlled Clinical Trial

Background: Osteoarthritis is a degenerative joint disorder of articular cartilage and is the most common type of arthritis in the elderly. There are only a few reports regarding the use of Hydroxychloroquine in the treatment of osteoarthritis. Methods: To investigate the effects of Hydroxychloroquine on the symptoms of mild to moderate knee osteoarthritis (Kellgren and Lawrence grade II and II...

full text

Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia.Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in ...

full text

Effect of Memantine on Positive Sign in Patients with Schizophrenia and Schizoaffective Disorders: A Randomized Double Blind Placebo Controlled Trial

Background and purpose: Memantine is a medication used to treat moderate to severe Alzheimer’s disease. Memantine targeting the glutamatergic system specifically N-Methyl-D-Aspartate offer a novel approach in treatment of psychiatric disorders such as schizophrenia and schizoaffective disorder. The purpose of this study was to evaluate the efficacy and safety of memantine in combination with an...

full text

INJECTION OF BOTULINUM TOXIN IN THE TREATMENT OF ACHALASIA: A RANDOMIZED, DOUBLE BLIND, CONTROLLED CLINICAL TRIAL

Our aim was to evaluate the short and long term efficacy of botulinum toxin therapy in Iranian patients with achalasia. In a randomized, double blind trial, 20 patients with achalasia, referring to Imam Khomeini Hospital, received either 80 units of botulinum toxin (BT) or placebo (PL) from 1995 to 1998. Two weeks later, the response to treatment was assessed on the basis of changes in the...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 7  issue 1

pages  7- 14

publication date 2019-03-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023